The Premier Gathering for the Life Science Anti-Corruption Community
Life sciences companies are navigating an increasingly complex anti-corruption landscape in 2025, marked by unprecedented shifts in FCPA enforcement priorities from the DOJ and sweeping policy changes under President Trump’s Executive Orders. As enforcement expectations evolve at home, global regulators are also tightening their grip, intensifying scrutiny, demanding greater corporate accountability, and heightening international enforcement standards.
It is now more important than ever that life sciences companies act decisively to reassess risk, recalibrate priorities, refine internal controls, and fortify global compliance frameworks.
ACI’s FCPA and Anti-Corruption Conference for the Life Sciences Industry is the premier event for compliance and legal professionals to benchmark strategies, engage directly with enforcement officials, and develop proactive approaches to mitigate corruption risks worldwide.
Conference Co-Chairs
Marc Hennes
Head of Legal Investigations
Novartis
Rebecca Orttel
Vice President, Chief Ethics & Compliance Officer for Operating Units
Medtronic
Featured Speakers
Jean-Francois Bohnert
Chief Public Prosecutor and Director
National Financial Prosecution Office (PNF) (France)
David Pitluck
Chief, Business and Securities Fraud Section
U.S. Attorney’s Office, Eastern District of New York
Amanda Page Masselam Strachan
Chief, Criminal Division
U.S. Attorney’s Office for the District of Massachusetts
Newly Revamped to Keep Up with Rapid Change Under Trump 2.0, Discover Fresh Formats, Innovative Topics and Practical Guidance Tailored to the Life Sciences Industry:
Who’s Doing What Since the Seismic Shift in FCPA Enforcement? How Life Sciences Companies Are Re-Ranking Risks and Rethinking Compliance Spend Amid Looming Uncertainty and Unintended Consequences
Strengthening Your Culture of Compliance Without the “Stick” of FCPA Enforcement: Reevaluating Strategies for Buy-In, Incentives, Voluntary Disclosures and Your Whistleblower Policies
Actionable Strategies for Doing Business in China: What It Takes to Thrive Amid the High-Risk Dynamics, New Healthcare Anti-Bribery Guidelines and Geopolitical Tensions
Spotlight on Latin America, Cartels and TCOs: Strengthening Anti-Corruption Oversight of Life Sciences Company Business Operations in Latin America Amidst DOJ’s New Crackdown on Cartels & TCOs
Utilizing AI and Data Analytics as Drivers of Compliance and Efficiencies: Life Sciences Companies Discuss New Approaches and Program Changes
Join New Smaller-Group Third-Party Management Focus Groups: New Best Practices for Mitigating Corruption Risks of Third-Party Business Dealings in the Pharmaceutical, Biotech, CRO and Medical Device Contexts
Who You Will Connect With
Compliance & Regulatory
General & In-House Counsel
Law Firm Partner
Accountants & Auditors
Connect with Industry Leaders Worldwide
Accreditation
Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as nontransitional for the purposes of CLE accreditation.
Learn more
An FCPA Enforcement Pause Does Not Pause Anti-Corruption Compliance
FCPA enforcement activity may be at a temporary standstill, but that should not mean much for the day-to-day operations of global anti-corruption compliance programs. If the Department of Justice’s shift in enforcement priorities means anything for legal and compliance, it might require shifting supply chain risk management and customer due diligence efforts.
View NowSponsor Opportunities
With conferences in the United States, Europe, Asia Pacific, and Latin America, the C5 Group of Companies: American Conference Institute, the Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.
For more information please contact:
Danny Maksad, Business Development Manager
Email: [email protected]
